The Mayo Clinic Alzheimer's Disease Research Center needs people to participate in research studies, including people with mild cognitive impairment, early dementia, Alzheimer's disease and Lewy body dementia. The Alzheimer's Disease Research Center also needs clinical trial participants who haven't been diagnosed with a memory disorder.

Learn more about clinical trials, the different types of clinical studies and deciding to volunteer for clinical studies.

Clinical Trials

Filter by condition

12 studies in Alzheimer's Disease Research Center

  1. Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia

    Rochester, Minn. View Summary

    Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    Identification of risk factors and biomarkers of neurodegenerative disease is essential in caring for the growing numbers of elderly. Imaging biomarkers provide non-invasive ways to look at brain function. A new PET imaging agent, Pittsburgh Compound B (PiB), that identifies brain amyloid is an exciting development in brain imaging that needs to be studied. We plan to study this imaging technique in normal volunteers and patients with a variety of neurodegenerative diseases to determine its utility. Long term followup of these subjects will allow us to understand the predictive ability of this new test.

    NCT ID:

    NCT00950430

    IRB Number:

    08-005553

    Who can I contact for additional information about this study?

  2. Bridging Study of C11 PiB and F18 Flutemetamol Brain PET

    Rochester, Minn. View Summary

    Bridging Study of C11 PiB and F18 Flutemetamol Brain PET

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    The intent of this research protocol is to test the equivalency of two amyloid imaging drugs (C11 Pittsburgh Compound B and F18 Flutemetamol). The investigators hypothesize that there will be no significant difference in the distribution of the agents to areas of amyloid deposition in the brain or to other normal brain structures. Recent data have shown similarity in the distribution of the drugs in subjects with AD or mild cognitive impairment (MCI). No comparison data of the two PET drugs in normal subjects has been published. It is important to understand differences in the images and biodistribution from the two drugs in normal subjects as nonspecific accumulation of the drugs in brain structures such as white matter appear to differ slightly and could affect image performance. The current clinical functional imaging standard for patients with indeterminate cognitive impairment is FDG PET. To allow a comparison of the PET amyloid imaging compounds with FDG PET, FDG PET scans will also be important to acquire in the subjects for comparison.

    NCT ID:

    NCT01607476

    IRB Number:

    12-000118

    Who can I contact for additional information about this study?

  1. Prev
  2. 1
  3. 2